OPR - Delayed Quote • USD ORIC May 2024 5.000 call (ORIC240517C00005000) Follow 2.4500 0.0000 (0.00%) As of November 16 at 12:52 PM EST. Market Open. Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for ORIC240517C00005000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: ORIC ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences How Much Upside is Left in Oric Pharmaceuticals (ORIC)? Wall Street Analysts Think 39.3% ORIC Pharmaceuticals Inc (ORIC) Reports Q4 and Full Year 2023 Financial Results ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates ORIC Pharmaceuticals Inc CEO Jacob Chacko Sells 40,000 Shares ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit ORIC Pharmaceuticals CEO Jacob Chacko Sells 40,000 Shares
